To appraise the clinical and cost effectiveness of sacituzumab govitecan within its marketing authorisation for treating unresectable locally advanced or metastatic triple-negative breast cancer after two or more therapies.
Status In progress
Process STA 2018
ID number 3942

Provisional Schedule

Expected publication 29 June 2022

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 June 2021 - 06 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
30 January 2018 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance